NO317659B1 - Syntetisk DNA som koder for gelonin-polypeptid, fremgangsmate for fremstilling av dette, samt en vertscelle som inneholder en ekspresjonsvektor omfattende nevnte syntetiske DNA - Google Patents
Syntetisk DNA som koder for gelonin-polypeptid, fremgangsmate for fremstilling av dette, samt en vertscelle som inneholder en ekspresjonsvektor omfattende nevnte syntetiske DNA Download PDFInfo
- Publication number
- NO317659B1 NO317659B1 NO19940736A NO940736A NO317659B1 NO 317659 B1 NO317659 B1 NO 317659B1 NO 19940736 A NO19940736 A NO 19940736A NO 940736 A NO940736 A NO 940736A NO 317659 B1 NO317659 B1 NO 317659B1
- Authority
- NO
- Norway
- Prior art keywords
- gene
- dna
- synthetic
- gelonin
- expression
- Prior art date
Links
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 title claims abstract description 72
- 239000013604 expression vector Substances 0.000 title claims abstract description 31
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 24
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 23
- 229920001184 polypeptide Polymers 0.000 title claims description 22
- 238000004519 manufacturing process Methods 0.000 title claims description 15
- 108700005078 Synthetic Genes Proteins 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 43
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 28
- 239000013598 vector Substances 0.000 claims abstract description 18
- 238000010367 cloning Methods 0.000 claims abstract description 17
- 239000002773 nucleotide Substances 0.000 claims abstract description 16
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 16
- 230000008569 process Effects 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 118
- 230000014509 gene expression Effects 0.000 claims description 54
- 108091034117 Oligonucleotide Proteins 0.000 claims description 52
- 108020004414 DNA Proteins 0.000 claims description 38
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 32
- 210000004027 cell Anatomy 0.000 claims description 31
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 239000012634 fragment Substances 0.000 claims description 23
- 108020004705 Codon Proteins 0.000 claims description 16
- 230000035772 mutation Effects 0.000 claims description 16
- 108091008146 restriction endonucleases Proteins 0.000 claims description 13
- 230000004927 fusion Effects 0.000 claims description 12
- 238000003786 synthesis reaction Methods 0.000 claims description 12
- 241000588724 Escherichia coli Species 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 102000053602 DNA Human genes 0.000 claims description 7
- 230000001413 cellular effect Effects 0.000 claims description 7
- 238000001243 protein synthesis Methods 0.000 claims description 7
- 230000014616 translation Effects 0.000 claims description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- 238000003776 cleavage reaction Methods 0.000 claims description 6
- 230000007017 scission Effects 0.000 claims description 6
- 238000002741 site-directed mutagenesis Methods 0.000 claims description 6
- 239000007790 solid phase Substances 0.000 claims description 6
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 5
- 241000196324 Embryophyta Species 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 102000006240 membrane receptors Human genes 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 239000013599 cloning vector Substances 0.000 claims description 4
- 238000012163 sequencing technique Methods 0.000 claims description 4
- 230000002194 synthesizing effect Effects 0.000 claims description 4
- 102000012410 DNA Ligases Human genes 0.000 claims description 3
- 108010061982 DNA Ligases Proteins 0.000 claims description 3
- 238000004458 analytical method Methods 0.000 claims description 3
- 230000002538 fungal effect Effects 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 2
- 230000009471 action Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 238000001502 gel electrophoresis Methods 0.000 claims description 2
- 230000026731 phosphorylation Effects 0.000 claims description 2
- 238000006366 phosphorylation reaction Methods 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims 3
- 241000238631 Hexapoda Species 0.000 claims 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 1
- 101710132601 Capsid protein Proteins 0.000 claims 1
- 101710094648 Coat protein Proteins 0.000 claims 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims 1
- 101710125418 Major capsid protein Proteins 0.000 claims 1
- 101710141454 Nucleoprotein Proteins 0.000 claims 1
- 101710083689 Probable capsid protein Proteins 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 239000012876 carrier material Substances 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 231100000742 Plant toxin Toxicity 0.000 abstract description 5
- 239000003123 plant toxin Substances 0.000 abstract description 5
- 230000002637 immunotoxin Effects 0.000 abstract description 3
- 239000002596 immunotoxin Substances 0.000 abstract description 3
- 231100000608 immunotoxin Toxicity 0.000 abstract description 3
- 229940051026 immunotoxin Drugs 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 10
- 108010039491 Ricin Proteins 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000010276 construction Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- 108010066676 Abrin Proteins 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- -1 gel37 Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- FKTJAQKUCINAIF-JNYDFHNISA-N 4-[(1r,2s,3s,4r)-4-(chloromethyl)-4-hydroxy-2-methoxy-3-[(2r,3r)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]cyclohexyl]oxy-4-oxobutanoic acid Chemical compound CO[C@@H]1[C@H](OC(=O)CCC(O)=O)CC[C@](O)(CCl)[C@H]1[C@]1(C)[C@@H](CC=C(C)C)O1 FKTJAQKUCINAIF-JNYDFHNISA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 101150078938 gel2 gene Proteins 0.000 description 2
- 101150022271 gel3 gene Proteins 0.000 description 2
- 101150077208 gel4 gene Proteins 0.000 description 2
- 238000003500 gene array Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000005291 magnetic effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 241000221018 Gelonium Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 101150012394 PHO5 gene Proteins 0.000 description 1
- 229940124154 Phospholipase inhibitor Drugs 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000012824 chemical production Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 231100000050 cytotoxic potential Toxicity 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 101150023545 gel1 gene Proteins 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 231100000110 immunotoxic Toxicity 0.000 description 1
- 230000002625 immunotoxic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000003428 phospholipase inhibitor Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75594991A | 1991-09-06 | 1991-09-06 | |
| PCT/US1992/007066 WO1993005168A1 (en) | 1991-09-06 | 1992-08-21 | Dna sequences encoding gelonin polypeptide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO940736D0 NO940736D0 (no) | 1994-03-03 |
| NO940736L NO940736L (no) | 1994-03-03 |
| NO317659B1 true NO317659B1 (no) | 2004-11-29 |
Family
ID=25041367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19940736A NO317659B1 (no) | 1991-09-06 | 1994-03-03 | Syntetisk DNA som koder for gelonin-polypeptid, fremgangsmate for fremstilling av dette, samt en vertscelle som inneholder en ekspresjonsvektor omfattende nevnte syntetiske DNA |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5624827A (zh) |
| EP (1) | EP0602144B1 (zh) |
| JP (1) | JPH06510431A (zh) |
| KR (1) | KR100270195B1 (zh) |
| CN (1) | CN1047402C (zh) |
| AT (1) | ATE173023T1 (zh) |
| AU (1) | AU679427B2 (zh) |
| CA (1) | CA2115049C (zh) |
| DE (1) | DE69227519T2 (zh) |
| DK (1) | DK0602144T3 (zh) |
| ES (1) | ES2123008T3 (zh) |
| FI (1) | FI113547B (zh) |
| IL (1) | IL103057A (zh) |
| NO (1) | NO317659B1 (zh) |
| NZ (1) | NZ244220A (zh) |
| RU (1) | RU2142015C1 (zh) |
| WO (1) | WO1993005168A1 (zh) |
| ZA (1) | ZA926705B (zh) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5317009A (en) * | 1991-08-26 | 1994-05-31 | New York University | Anti-HIV proteins GAP 31, DAP 30 and DAP 32 and therapeutic uses thereof |
| US6146850A (en) * | 1991-11-04 | 2000-11-14 | Xoma Corporation | Proteins encoding gelonin sequences |
| US5837491A (en) * | 1991-11-04 | 1998-11-17 | Xoma Corporation | Polynucleotides encoding gelonin sequences |
| US5621083A (en) * | 1991-11-04 | 1997-04-15 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
| US5869619A (en) * | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| US5766886A (en) * | 1991-12-13 | 1998-06-16 | Xoma Corporation | Modified antibody variable domains |
| CA2162689C (en) * | 1993-05-12 | 2000-07-18 | Marc D. Better | Immunotoxins comprising gelonin and an antibody |
| US20030166169A1 (en) * | 1998-01-16 | 2003-09-04 | Padgett Hal S. | Method for constructing viral nucleic acids in a cell-free manner |
| ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
| IL159894A0 (en) | 2001-07-17 | 2004-06-20 | Res Dev Foundation | Therapeutic agents comprising pro-apoptotic proteins |
| AU2003275985A1 (en) * | 2002-06-12 | 2003-12-31 | Research Development Foundation | Immunotoxin as a therapeutic agent and uses thereof |
| WO2004035537A2 (en) | 2002-10-16 | 2004-04-29 | Euro-Celtique S.A. | Antibodies that bind cell-associated ca 125/o772p and methods of use thereof |
| AU2006210769A1 (en) * | 2005-02-01 | 2006-08-10 | Research Development Foundation | BLyS fusion proteins for targeting BLyS receptor and methods for treatment of B-cell proliferative disorders |
| KR101224828B1 (ko) * | 2009-05-14 | 2013-01-22 | (주)바이오니아 | ｓｉＲＮＡ 접합체 및 그 제조방법 |
| US8759036B2 (en) * | 2011-03-21 | 2014-06-24 | Affymetrix, Inc. | Methods for synthesizing pools of probes |
| CN107058059B (zh) | 2011-09-26 | 2020-08-07 | 基因技术股份公司 | 高效的小体积核酸合成 |
| WO2014153188A2 (en) | 2013-03-14 | 2014-09-25 | Life Technologies Corporation | High efficiency, small volume nucleic acid synthesis |
| EP2904004B1 (en) | 2012-10-04 | 2018-11-21 | Research Development Foundation | Serine protease molecules and therapies |
| EP3557262B1 (en) | 2014-12-09 | 2022-08-10 | Life Technologies Corporation | High efficiency, small volume nucleic acid synthesis |
| US20180291413A1 (en) | 2015-10-06 | 2018-10-11 | Thermo Fisher Scientific Geneart Gmbh | Devices and methods for producing nucleic acids and proteins |
| WO2020001783A1 (en) | 2018-06-29 | 2020-01-02 | Thermo Fisher Scientific Geneart Gmbh | High throughput assembly of nucleic acid molecules |
| GB201905303D0 (en) | 2019-04-15 | 2019-05-29 | Thermo Fisher Scient Geneart Gmbh | Multiplex assembly of nucleic acid molecules |
| WO2021178809A1 (en) | 2020-03-06 | 2021-09-10 | Life Technologies Corporation | High sequence fidelity nucleic acid synthesis and assembly |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4888415A (en) * | 1985-03-04 | 1989-12-19 | Dana-Farber Cancer Institute, Inc. | Gelonin immunotoxin |
| US5024947A (en) * | 1987-07-24 | 1991-06-18 | Cetus Corporation | Serum free media for the growth on insect cells and expression of products thereby |
| US5290914A (en) * | 1988-04-28 | 1994-03-01 | Mycogen Corporation | Hybrid diphtheria-B.t. pesticidal toxins |
| IE912716A1 (en) * | 1990-08-14 | 1992-02-26 | Res Dev Foundation | Protein Structure of the Plant Toxin Gelonin |
-
1992
- 1992-08-21 DE DE69227519T patent/DE69227519T2/de not_active Expired - Lifetime
- 1992-08-21 WO PCT/US1992/007066 patent/WO1993005168A1/en active IP Right Grant
- 1992-08-21 AU AU25476/92A patent/AU679427B2/en not_active Ceased
- 1992-08-21 ES ES92919264T patent/ES2123008T3/es not_active Expired - Lifetime
- 1992-08-21 DK DK92919264T patent/DK0602144T3/da active
- 1992-08-21 CA CA002115049A patent/CA2115049C/en not_active Expired - Fee Related
- 1992-08-21 RU RU94034733A patent/RU2142015C1/ru not_active IP Right Cessation
- 1992-08-21 KR KR1019940700732A patent/KR100270195B1/ko not_active IP Right Cessation
- 1992-08-21 JP JP5505226A patent/JPH06510431A/ja active Pending
- 1992-08-21 AT AT92919264T patent/ATE173023T1/de not_active IP Right Cessation
- 1992-08-21 EP EP92919264A patent/EP0602144B1/en not_active Expired - Lifetime
- 1992-09-04 ZA ZA926705A patent/ZA926705B/xx unknown
- 1992-09-04 CN CN92110105A patent/CN1047402C/zh not_active Expired - Fee Related
- 1992-09-04 IL IL10305792A patent/IL103057A/en not_active IP Right Cessation
- 1992-09-04 NZ NZ244220A patent/NZ244220A/en not_active IP Right Cessation
-
1994
- 1994-03-03 NO NO19940736A patent/NO317659B1/no not_active IP Right Cessation
- 1994-03-04 FI FI941048A patent/FI113547B/fi active
- 1994-10-21 US US08/327,440 patent/US5624827A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69227519D1 (de) | 1998-12-10 |
| CA2115049C (en) | 2003-10-21 |
| RU2142015C1 (ru) | 1999-11-27 |
| EP0602144A1 (en) | 1994-06-22 |
| NZ244220A (en) | 1994-12-22 |
| NO940736D0 (no) | 1994-03-03 |
| NO940736L (no) | 1994-03-03 |
| AU2547692A (en) | 1993-04-05 |
| JPH06510431A (ja) | 1994-11-24 |
| RU94034733A (ru) | 1996-06-10 |
| AU679427B2 (en) | 1997-07-03 |
| IL103057A (en) | 1999-09-22 |
| FI113547B (fi) | 2004-05-14 |
| WO1993005168A1 (en) | 1993-03-18 |
| IL103057A0 (en) | 1993-02-21 |
| DE69227519T2 (de) | 1999-06-02 |
| EP0602144B1 (en) | 1998-11-04 |
| ZA926705B (en) | 1993-04-28 |
| CA2115049A1 (en) | 1993-03-18 |
| DK0602144T3 (da) | 1999-07-19 |
| FI941048A0 (fi) | 1994-03-04 |
| FI941048A (fi) | 1994-03-04 |
| EP0602144A4 (en) | 1995-03-15 |
| ES2123008T3 (es) | 1999-01-01 |
| ATE173023T1 (de) | 1998-11-15 |
| CN1047402C (zh) | 1999-12-15 |
| KR100270195B1 (ko) | 2001-03-02 |
| CN1070227A (zh) | 1993-03-24 |
| US5624827A (en) | 1997-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO317659B1 (no) | Syntetisk DNA som koder for gelonin-polypeptid, fremgangsmate for fremstilling av dette, samt en vertscelle som inneholder en ekspresjonsvektor omfattende nevnte syntetiske DNA | |
| EP0938571B1 (en) | Method for the oligomerisation of peptides | |
| CA2378871A1 (en) | Design of beta-sheet proteins with specific binding properties | |
| CZ264496A3 (en) | Increase of polypeptide secretion | |
| JPH02500876A (ja) | 組換えポリペプチドの製品およびその製造、単離および精製方法 | |
| EP0150572A1 (en) | Microbial expression of type 1 transforming growth factor, polypeptide analogs thereof and hybrid EGF/TGF polypeptides | |
| JPS62501538A (ja) | ａｒａＢプロモーターを含有する複製可能な発現ビヒクル | |
| US6191258B1 (en) | Purified palindromic element binding factor | |
| EP0321940B1 (en) | An improved method for the preparation of natural human growth hormone in pure form | |
| PT614982E (pt) | Vector recombinante e o seu uso para a preparacao exocelular de anticorpos sob a forma de molecula unica a partir de bacillus subtilis | |
| Tamás et al. | Heterologous expression and protein engineering of wheat gluten proteins | |
| JP2612264B2 (ja) | Ｄｎａ配列体 | |
| Lepage et al. | Recombinant technology as an alternative to chemical peptide synthesis: Expression and characterization of HIV-1 Rev recombinant peptides | |
| JPH0638771A (ja) | ヒトプロテインジスルフィドイソメラーゼ遺伝子の発現方法および該遺伝子との共発現によるポリペプチドの製造方法 | |
| JPS62232387A (ja) | 組換リシントキシン | |
| Burks et al. | Rapid, High‐Yield Recovery of a Recombinant Digoxin Binding Single Chain Fv from Escherichia coli | |
| KR101747701B1 (ko) | 재조합 덱스트란슈크라제 발현 벡터 및 이 덱스트란슈크라제를 이용한 파노오스의 제조 방법 | |
| KR940004543B1 (ko) | 이.콜라이의 trp 발현 시스템을 갖는 벡터를 제조하는 방법 | |
| KR20030034136A (ko) | 양이온성 아미노산이 부가된 융합단백질 및 이를 이용한생물공정의 개선방법 | |
| JPH02227079A (ja) | ヒト血清アルブミン断片 | |
| JPH0928380A (ja) | ニトリラーゼ遺伝子発現に関わる調節因子およびその遺伝子 | |
| JP2003079379A (ja) | 成長ホルモンの高発現用ｄｎａおよびその使用 | |
| KR20210079235A (ko) | Whep 도메인 융합에 의한 목적 단백질의 수용성 증진 방법 | |
| KR920003665B1 (ko) | 합성유전자에 의한 대장균으로부터 소성장호르몬의 대량 생산방법 | |
| WO1989009776A1 (en) | VirE OPERON-ENCODED POLYPEPTIDES THAT BIND SINGLE-STRANDED DNA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |